Skip to main content

ASCPT 2023 Annual Meeting Main banner

Tweets by ASCPT 2023 Annual Meeting

Browse by Poster Title

Browse by Poster Title

Type here to filter the list

All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
#

D
PI-014
DETERMINATION OF ABSOLUTE BIOAVAILABILITY OF QUIZARTINIB USING A MICROTRACER.

Favorite
PI-053
DEVELOPING A MECHANISTIC MODEL OF IL-15 MEDIATED NK CELL PROLIFERATION WITH IMPLICATIONS IN IMPROVING CAR NK CELL THERAPY EFFICACY.

Favorite
PI-077
DEVELOPMENT AND VERIFICATION OF A PYRIDOXIC ACID PBPK MODEL TO EVALUATE BIOMARKER INFORMED ORGANIC ANION TRANSPORTERS (OAT) 1 AND 3 INHIBITION.

Favorite
PII-002
DEVELOPMENT OF A MULTISCALE MECHNISM-BASED CELLULAR KINETIC-PHARMACODYNAMIC (CK-PD) MODEL FOR DUAL-TARGETED BICISTRONIC CAR-T CELL THERAPY.

Favorite
PI-054
DEVELOPMENT OF A PHARMACOKINETIC-PHARMACODYNAMIC MODEL FOR MRNA-0184, AN INVESTIGATIONAL MRNA THERAPEUTIC ENCODING HUMAN RELAXIN-2-VLK FOR THE TREATMENT OF HEART FAILURE.

Favorite
LB-008
DEVELOPMENT OF HOLISTIC EXPOSURE-TOXICITY RELATIONSHIPS FOR MMAE-BASED ADCS: A GENERALIZED PK/PD MODEL.

Favorite
PI-096
DEVELOPMENT OF IMMUNO-ONCOLOGY (IO) QSP PLATFORM MODEL FOR EFFICACY PREDICTION OF CHECKPOINT INHIBITORS (CPI) AND ADC COMBINATION THERAPY IN PHASE II/III CLINICAL TRIALS.

Favorite
PT-023
DEVELOPMENT OF INTRANASAL PHYSIOLOGICALLY BASED NOSE TO BRAIN MODEL AND ITS APPLICATION TO CHARACTERIZE IN NEUROEPO ABSORPTION VIA NASAL ROUTE AND DISTRIBUTION TO LUMBAR CSF IN HEALTHY NON-HUMAN PRIMATES (CYANOMOLGUS MONKEY).

Favorite
EP-013
DEVELOPMENT OF POPULATION PHARMACOKINETICS MODEL OF PYRAZINAMIDE AND OPTIMAL DOSE RECOMMENDATION FOR ELDERLY WITH DIABETES MELLITUS IN KOREAN TUBERCULOSIS PATIENTS.

Favorite
PII-125
DEVELOPMENT OF RHEUMATOID ARTHRITIS QSP MODEL FOR TRIAL SIMULATION AND PREDICTING RESPONSE TO NOVEL COMBINATIONS.

Favorite
PI-015
DEVELOPMENT OF USER-FRIENDLY BAYESIAN PREDICTIVE PLATFORM FOR BLOOD BORON-10 PHARMACOKINETICS FOLLOWING INTRAVENOUS INFUSION OF [10B]L-4-BORONOPHENYLALANINE.

Favorite
PI-087
DEVELOPMENTAL CHANGES OF HYDROXYUREA PHARMACOKINETICS IN CHILDREN WITH SICKLE CELL ANEMIA.

Favorite
PWIV-003
DEVELOPMENTAL CHANGES OF HYDROXYUREA PHARMACOKINETICS IN CHILDREN WITH SICKLE CELL ANEMIA.

Favorite
PT-027
DO GLUCOSE-LOWERING DRUGS AFFECT DRUG METABOLISM AND WARFARIN EFFICACY?

Favorite
PI-025
DOCUMENTATION OF RESULTS AND MEDICATION PRESCRIBING AFTER COMBINATORIAL PSYCHIATRIC PHARMACOGENETIC TESTING.

Favorite
PI-055
DOSE SELECTION FOR BRIGATINIB TO SUPPORT PEDIATRIC DEVELOPMENT.

Favorite
PI-056
DOSE SELECTION FOR MITAPIVAT PEDIATRIC PHASE 3 STUDIES USING POPULATION PHARMACOKINETIC MODELING AND SIMULATION.

Favorite
PI-057
DOSE–RESPONSE MODEL PREDICTIONS OF THE PHARMACODYNAMIC EFFECT OF BEMPEDOIC ACID, A COMPETITIVE INHIBITOR OF ATP CITRATE LYASE, IN COMBINATION WITH EZETIMIBE AND STATINS.

Favorite
PII-011
DRUG-DRUG INTERACTION BETWEEN THE NOVEL SODIUM-GLUCOSE COTRANSPORTER-2 INHIBITOR, DWP16001, WITH GEMIGLIPTIN AND METFORMIN IN HEALTHY SUBJECTS.

Favorite
PI-058
DRUG-DRUG INTERACTION POTENTIAL OF MAVACAMTEN WITH ORAL CONTRACEPTIVES: RESULTS FROM A CLINICAL PHARMACOKINETIC STUDY.

Favorite